Aduro BioTech Inc (NASDAQ:ADRO) EVP Dirk G. Brockstedt sold 65,223 shares of the stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $8.11, for a total value of $528,958.53. Following the transaction, the executive vice president now owns 137,826 shares in the company, valued at approximately $1,117,768.86. The sale was disclosed in a document filed with the SEC, which is available through this link.

Shares of Aduro BioTech Inc (NASDAQ ADRO) traded up $0.10 on Friday, hitting $8.20. The company’s stock had a trading volume of 1,516,344 shares, compared to its average volume of 420,348. Aduro BioTech Inc has a twelve month low of $6.01 and a twelve month high of $14.05.

Aduro BioTech (NASDAQ:ADRO) last issued its earnings results on Tuesday, October 31st. The biotechnology company reported ($0.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.03). Aduro BioTech had a negative return on equity of 39.28% and a negative net margin of 548.92%. The company had revenue of $3.79 million during the quarter, compared to analyst estimates of $4.04 million. During the same period last year, the business earned ($0.54) earnings per share. The firm’s revenue was up .0% compared to the same quarter last year. sell-side analysts anticipate that Aduro BioTech Inc will post -1.28 earnings per share for the current fiscal year.

A number of brokerages have weighed in on ADRO. HC Wainwright set a $18.00 price objective on Aduro BioTech and gave the company a “buy” rating in a report on Wednesday, November 1st. Oppenheimer decreased their price objective on Aduro BioTech from $15.00 to $13.00 and set an “outperform” rating on the stock in a report on Wednesday. William Blair restated an “outperform” rating on shares of Aduro BioTech in a report on Monday, October 2nd. Canaccord Genuity set a $30.00 price objective on Aduro BioTech and gave the company a “buy” rating in a report on Thursday. Finally, BidaskClub lowered Aduro BioTech from a “hold” rating to a “sell” rating in a report on Saturday, December 9th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $17.64.

Several institutional investors and hedge funds have recently modified their holdings of the business. Harvard Management Co. Inc. acquired a new stake in shares of Aduro BioTech in the 3rd quarter worth $69,418,000. Vanguard Group Inc. increased its position in shares of Aduro BioTech by 5.4% during the 2nd quarter. Vanguard Group Inc. now owns 2,511,995 shares of the biotechnology company’s stock worth $28,637,000 after purchasing an additional 129,079 shares during the last quarter. State Street Corp increased its position in shares of Aduro BioTech by 8.3% during the 2nd quarter. State Street Corp now owns 684,699 shares of the biotechnology company’s stock worth $7,808,000 after purchasing an additional 52,597 shares during the last quarter. Baillie Gifford & Co. increased its position in shares of Aduro BioTech by 30.8% during the 3rd quarter. Baillie Gifford & Co. now owns 553,090 shares of the biotechnology company’s stock worth $5,891,000 after purchasing an additional 130,390 shares during the last quarter. Finally, Northern Trust Corp increased its position in shares of Aduro BioTech by 15.1% during the 2nd quarter. Northern Trust Corp now owns 453,115 shares of the biotechnology company’s stock worth $5,166,000 after purchasing an additional 59,490 shares during the last quarter. 45.19% of the stock is owned by institutional investors and hedge funds.

WARNING: “Aduro BioTech Inc (ADRO) EVP Sells $528,958.53 in Stock” was first reported by American Banking News and is the property of of American Banking News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this news story can be read at https://www.americanbankingnews.com/2017/12/15/aduro-biotech-inc-adro-evp-sells-528958-53-in-stock.html.

Aduro BioTech Company Profile

Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.

Insider Buying and Selling by Quarter for Aduro BioTech (NASDAQ:ADRO)

Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.